The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.
Categories:
Related Post
Latest Producer Price Index report offers little relief
Domestic producers are “raising prices in line with the protection tariffs are providing them,” said…
Skanska Koch taps new general manager
Michael Donohue will take over for company veteran Bill Matre, who joined the firm in…
Digital permitting, AI tools top of mind for NIBS panelists
During the National Institute of Building Sciences Building Innovation conference, speakers pointed to how digital…